Glenmede Investment Management’s Castle Biosciences CSTL Stock Holding History

Glenmede Investment Management’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$232K	Buy	+10,199	New	+$207K	﹤0.01%	1214

Other funds holding CSTL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glenmede Investment Management's CSTL Position: Q3 2025 in Review

Glenmede Investment Management opened a new position in Castle Biosciences (CSTL) in Q3 2025: 10,199 shares worth $232K. The stake represents ﹤0.01% of the portfolio and ranks #1214 among its holdings.

173 funds tracked by Wall St. Rank hold CSTL as of Q3 2025.

Glenmede Investment Management held 10,199 shares of Castle Biosciences worth $232K as of Q3 2025.
Castle Biosciences was a new Glenmede Investment Management position in Q3 2025.
Castle Biosciences made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #1214 holding.
173 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.